Pulmonary arterial hypertension (PAH) is a type of pulmonary hypertension that causes high blood pressure in the small arteries of the lungs. It is a serious condition that can impair blood flow ...

mitochondrial abnormalities and thrombosis are the dominant underlying pathobiologic processes of pulmonary arterial hypertension (PAH). In addition to conventional and supportive therapies ...

Pulmonary arterial hypertension (PAH) is a rare and severe lung disease with a life-threatening prognosis. After several positive trials, a recent study has confirmed the efficacy of a biotherapy, ...

Hypertension does not directly cause dyspnoea; however it can lead to long-term effects on the heart and arteries ...

Treatments approved for PAH may reduce by half the risk of serious complications or death in patients with repaired ...

Venous hypertension affects veins in the legs and the way blood circulates to the heart. Learn about symptoms of venous ...

The following is a summary of “Right atrial reservoir strain as an early predictor of pulmonary hypertension development in ...

Pulmonary artery denervation in pulmonary hypertension: A comprehensive meta-analysis, has shed light on the potential of pulmonary artery denervation (PADN) as an innovative intervention for ...

"Pulmonary artery denervation in pulmonary hypertension: A comprehensive meta-analysis" has shed light on the potential of pulmonary artery denervation (PADN) as an innovative intervention for ...

CHICAGO -- Adding sotatercept (Winrevair) to the treatment regimen for pulmonary arterial hypertension (PAH) in high-risk patients helped delay serious outcomes in the ZENITH trial. Among 172 ...

Sotatercept improves exercise capacity and delays the time to clinical worsening in patients with World Health Organization (WHO) functional class II or III pulmonary arterial hypertension.